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The tumour microenvironment is very complex, and essential in tumour development and drug 
resistance. The endothelium is critical in the tumour microenvironment: it provides nutrients and 
oxygen to the tumour and is essential for systemic drug delivery. Therefore, we report a simple, user-
friendly microfluidic device for co-culture of a 3D breast tumour model and a 2D endothelium model for 
cross-talk and drug delivery studies. First, we demonstrated the endothelium was functional, whereas 
the tumour model exhibited in vivo features, e.g., oxygen gradients and preferential proliferation of 
cells with better access to nutrients and oxygen. Next, we observed the endothelium structure lost its 
integrity in the co-culture. Following this, we evaluated two drug formulations of TRAIL (TNF-related 
apoptosis inducing ligand): soluble and anchored to a LUV (large unilamellar vesicle). Both diffused 
through the endothelium, LUV-TRAIL being more efficient in killing tumour cells, showing no effect on 
the integrity of endothelium. Overall, we have developed a simple capillary force-based microfluidic 
device for 2D and 3D cell co-cultures. Our device allows high-throughput approaches, patterning 
different cell types and generating gradients without specialised equipment. We anticipate this 
microfluidic device will facilitate drug screening in a relevant microenvironment thanks to its simple, 
effective and user-friendly operation.
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Our understanding of cancer has undergone significant changes in the last years. We used to think of cancer as a 
clonally expanded cell population originated from a single cell1. However, it is now evident that tumours consist 
of highly complex systems, where the tumour microenvironment plays a fundamental role2. Spatial and tempo-
ral complexities (such as biochemical signals and gradients thereof), together with the variety of cell types and 
phenotype differences within the same cell type add up to compose this orchestrated environment in tumour 
tissues, which is known as the tumour microenvironment (TME)2–5. It has been previously reported that this high 
complexity and heterogeneity play a significant role in drug resistance. Moreover, tumour cells also interact with 
the stroma, conditioning the initiation of the disease, development, and resistance to therapy6.
Furthermore, the endothelium plays a significant role in cancer development and drug delivery. The endothe-
lium regulates nutrient diffusion and responds to hypoxic signals produced by tumour cells to promote new 
blood vessel formation via angiogenesis. Additionally, blood vessel permeability is essential for the delivery of 
drugs to cancer cells, which, in turn, determines the overall effect of the drug on the patient7,8. Of particular 
interest is the Enhanced Permeability and Retention (EPR) effect, which is caused by the generation of a porous 
architecture in the blood vessels surrounding the solid tumours, leading to an increased vascular permeabil-
ity. The EPR effect results in more efficient oxygen and nutrient supply to the tumour sites than from regular 
vessels8. Likewise, nanomedicine-based treatments take advantage of this EPR effect for the local accumulation 
of nano-vehicled agents, which are meant for diagnostic or therapeutic purposes8. Currently, the delivery and 
efficiency of treatments against cancer disease are still mostly tested in classical in vitro 2D models9–11, which 
usually lack an extracellular matrix, do not include different cell types arranged in a structured manner and lack 
biochemical gradients (e.g., of oxygen and nutrients). Consequently, 2D models are unable to faithfully reproduce 
the tumour-endothelium interactions, where crosstalk depends on a 3D environment, as well as on direct cell-cell 
interactions in a 3D manner. Of particular interest for the generation of sophisticated models are the so-called 
organ-on-a-chip platforms, which combine different cell types and microfabricated structures and allow mim-
icking the architecture of a whole organ and/or tissues12. Such microfluidic technology shows great potential in 
the field of cancer research to faithfully mimic the TME13. To date, significant efforts in the field of microfluidics 
have focused in reproducing the tumour microenvironment, and, in particular, studying the interactions of can-
cer cells and the endothelium14–17. For instance, the Kamm group has established co-culture of breast cancer cells 
and endothelial cells to study cellular extravasation and vascular permeability18, as well as tissue-specific metas-
tasis15,19. Additionally, they successfully characterised molecular mechanisms of metastasis in breast cancer20–22, 
and macrophage extravasation. Also worth mentioning are the efforts in establishing distinctively patterned 
co-cultures made by the Beebe group for drug screening and biosensing applications23,24. Interested readers in 
microfluidic cell culture approaches in cancer are referred to excellent reviews by Sung et al., Portillo-Lara et al. 
and Regier et al.25–27.
From these different examples, we can infer that despite all these efforts, microfluidic technology remains 
restricted to engineering laboratories and has mainly focused on proof-of-concept applications. The fact that 
microfluidics is rarely used in traditional cell biology laboratories can be explained by the high difficulty of oper-
ation and low- or medium-throughput of most microdevices28,29. Therefore, to bridge the gap between micro-
fluidics and basic and translational research laboratories, a new generation of microdevices is needed, which 
balances the simplicity of operation, reproducibility, biological relevance and usefulness in the described contexts. 
Additionally, integration of endothelial layers in microfluidic models has also proven difficult. This integration 
requires a continuous interface to provide support and allow endothelial cells to attach correctly. Furthermore, a 
common method to assess endothelium integrity in vitro relies on TEER (TransEpithelial Electrical Resistance) 
measurements30,31. Nonetheless, this approach presents a few drawbacks, which limit its applicability. Namely, 
it requires the integration of an electrical setup within the biological setup; it requires specific electrodes to be 
built-in or added externally to the microfluidic system; and, more importantly, the lack of stability for these meas-
urements is a well-known problem, which yet, remains to be overcome32. Optimised optical inspection and easy 
access to the endothelium would provide not only an advantageous alternative but also additional information on 
cell morphology and tight junctions in the endothelium using immunofluorescent staining.
In this context, we present here a simple and self-filling SU-8-based microdevice design, which exploits cap-
illary forces, to study endothelium-tumour interactions. The proposed design consists of several linear arrays 
of microwells (Fig. 1c), in which 3D tumour models are created by embedding tumour cells in a 3D collagen 
matrix and, on top of which confluent HUVEC monolayers are prepared as 2D mimics of the endothelial barrier. 
Although similar approaches have already been reported33, our device allows filling an array of microwells in 
only one single pipetting step and a few seconds, fulfilling thereby the key requirements of simplicity of oper-
ation and user-friendliness. Additionally, the design of the microdevice has been optimised for optical exami-
nation of the endothelium to evaluate its integrity. This approach can replace TEER measurements for an easier 
and more comprehensive approach to endothelium integrity. Here, we first demonstrated co-culture of breast 
tumour cells (MDA-MB-231) seeded in 3D with an endothelium (HUVEC) and thoroughly characterised these 
models (Fig. 1a). Next, we applied our model to study the cytotoxic effects of drugs and their penetration in the 
3D tumour environment. To that end, the anti-tumour agent TNF-related apoptosis-inducing ligand (TRAIL) 
was evaluated. TRAIL is a protein secreted by immune cells, and which can induce apoptosis in malfunctioning 
cells34. In vivo, TRAIL is secreted as anchored to liposomes, and this clustered form has been found to have a 
higher potential for inducing apoptosis35. Here, two different drug formulations were therefore tested; a soluble 
version (sTRAIL) and an “improved” formulation based on liposomes decorated with TRAIL (LUV-TRAIL). 
Altogether, we have developed a simple and highly versatile microfluidic device design with a physiologically 
relevant tumour-endothelium co-culture model, which allows testing the penetration and efficiency of drugs on 
tumour tissues.
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Figure 1. Experimental configuration and microdevice fabrication: (a) Scheme of the 3D tumor-2D 
endothelium co-culture model recreated in the present study within the device; (b) Chip fabrication process 
flow: (1) Kapton film bonding to a pyrex wafer, (2) deposition of a 90-µm thick SU-8 layer, UV-exposure and 
polymerization of the microchannel and microwell structures, (3) spinning of a 90- µm thick SU-8 layer and 
patterning of the microchannel and microwell structures, (4) development of the two SU-8 layers, (5) Kapton 
film bonding to a pyrex wafer, (6) spinning of a 90-µm thick SU-8 layer and patterning by photolithography, (7) 
cover development, (8) SU-8 to SU-8 thermal bonding, (9) SU-8 device release. (c) Schematic representation of 
an open device, showing the different SU-8 layers: the bottom layer (blue) the channel layer (red), including the 
channels and microwells and a top layer (grey) with microwell structures to yield open microwells and closed 
microchannels; (d) Photography of a final microdevice consisting of 3 arrays of 5 microwells each.
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Results
Hydrophilic features and liquid handling within the microdevice. SU-8 was selected as a building 
material due to its previously reported biocompatibility in cell culture applications36,37, as well as some additional 
intrinsic advantages over native PDMS (Polydimethylsiloxane) for the fabrication of cell culture systems. These 
advantages include broader chamber design possibilities38, convenient mechanical properties39, monolithic inte-
gration with a variety of sensors and, importantly in our case, low gas permeability40, which facilitates the creation 
of an oxygen gradient without any need for external systems. SU-8, provides a high degree of control over the fab-
ricated structures and capillary valves, as included here. Once the microdevices were fabricated (Fig. 1), they were 
treated with O2 plasma to promote spontaneous filling of the devices. Following this treatment, the contact angle 
was reduced from 82.6 ± 1.6° to 21.1 ± 2.3° (N = 10, Supplementary Fig. S1), and spontaneous hydrogel intro-
duction was observed in the microwell arrays (Fig. 2b, left panels). This behaviour was also expected according 
to the microdevice design. Besides, spontaneous microdevice filling occurred in a few seconds, ensuring thereby 
that the hydrogel filled the microdevice completely before collagen polymerization would occur. Interestingly, 
in the absence of plasma treatment, capillary forces were not strong enough to fill the microdevice completely, 
and hydrogel injection was extremely slow. Consequently, the hydrogel remained pinned in the microchannels 
connecting the microwells without filling the entire microdevice (Fig. 2b, right panels).
Air-hydrogel interface analysis and optimisation in the microdevice. Next, we characterised the 
air-hydrogel interface in the microdevice after collagen polymerization to ensure that a flat interface was created, 
which is essential for cell imaging. To that end, the microdevice was filled with collagen supplemented with 
FluoSpheres® and the interface was characterised both immediately after filling the microdevice and after colla-
gen polymerization.
The interface was flat immediately after collagen perfusion (Fig. 2c), showing a homogeneous distribution of 
the FluoSpheres® in the hydrogel. However, after polymerization a 200 μm-deep meniscus appeared, causing the 
Fluosphere® microbeads to cluster in the centre at the interface (Fig. 2d). We assumed this meniscus was created 
due to water evaporation during the polymerization process at 37 °C within the incubator. Therefore, to avoid the 
formation of such a meniscus, we placed a hydrogel droplet at the device inlet (Fig. 2e) to counteract evaporation. 
As presented in Fig. 2a, the pressure exerted by the droplet was enough to maintain a flat air-liquid interface dur-
ing the whole hydrogel polymerization process, by compensating any evaporation of the solution.
Microdevice biocompatibility and characterization of the 3D cell culture microenviron-
ment. As a next step, cell viability was examined in 3D culture in the collagen to confirm the device bio-
compatibility. Therefore, we seeded MDA-MB-231 breast tumour cells at a final density of 5 × 106 cells/ml in a 
1.2 mg/ml collagen hydrogel. After three days in culture, cell viability was assessed with calcein AM (green) and 
propidium iodide (red). Through this method, live cells were stained in green, whereas dead cells were stained 
in red. Cell viability inside the microdevice was similar to that observed for control hydrogels also loaded with 
the same number of cells but cultured on a Petri dish (Fig. 3a–c), and in both cases, a cell viability higher than 
98% was observed. Additionally, we evaluated the three-dimensional cell distribution along the microwell height. 
Typically, cells would occupy between 15 and 30% of the surface area of the microwell in each 10 µm-thick layer 
imaged by confocal microscopy, and no significant difference was observed throughout the whole well height 
(Fig. 3d). Altogether, there was no significant accumulation of cells at a specific height in the collagen in the 
microwells, and no sedimentation of the cells at the bottom of the microwells.
Furthermore, we characterised the tumour cell behaviour and function within the microwells. Firstly, we 
investigated cell proliferation for different cell seeding densities (0.4 × 106, 2 × 106 and 107 cells/ml) using 
Premo® FUCCI Cell Cycle Indicator, which stains G0/G1 phase cells in red and S, G2 and M phase cells in green. 
MDA-MB-231 tumour cells embedded in the collagen gel were transfected with this proliferation marker within 
each independent array of microwells in a single microdevice, and the proliferation index of cells was determined 
as the number of cells in G2/M/S divided by the total number of seeded cells. Results revealed that the prolifera-
tion index significantly diminished for higher cell concentrations (Fig. 3e). Specifically, a 5-fold cell concentration 
increase (from 0.4 × 106 to 2 × 106 cells/ml) was accompanied by a reduction in proliferation to 53.3%, and a 
4-fold increase in concentration by a 28.7% decrease in proliferation (Supplementary Fig. S4).
Proliferation differences can be accounted for variations in nutrient and oxygen availability. To test this 
hypothesis –i.e., if there was a significant change in oxygen concentration depending on the cell concentra-
tion, we checked for the possible depletion of oxygen within the microwells. For this experiment, we compared 
microwells prepared with either high or low cell concentrations in collagen hydrogels. The graph presenting these 
results in Fig. 3f indicates significantly different oxygen concentration profiles for the two cell densities tested here 
(0.4 × 106 and 107 cells/ml). For a low cell concentration (0.4 × 106 cells/ml), a low and constant fluorescence level 
was found throughout the entire height of the microwell after 24 h, indicating a normal oxygen level. In contrast, a 
gradient in oxygen concentration was observed for the high cell concentration (107 cells/ml) with marked oxygen 
depletion at the bottom of the well after 24 h of culture under the same conditions (Fig. 3f). Altogether, the culture 
of cells in the hydrogel in the microwells beyond a certain cell concentration threshold resulted in the appearance 
of deprived oxygen conditions, which could explain the marked decrease we record regarding cell proliferation, 
as initially hypothesised. Furthermore, with our model, we were able to mimic the typical architecture found in 
tumour tissues in vivo, which typically contain a hypoxic non-proliferating core and a proliferative periphery with 
direct access to oxygen41. This structure is particularly relevant to assess the efficiency of drugs, since some drugs 
are more effective on proliferating cells and not active under hypoxic conditions, while other drugs are specifically 
activated in an oxygen-poor environment42.
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Characterisation of the endothelial barrier model. The second main component of the co-culture 
is the endothelium layer on top of the 3D culture in each microwell. The endothelium was created by seeding 
HUVEC cells (firstly phenotyped, data available in Supplementary Fig. S2) at a density of 250,000 cells/cm2 on 
microwells in a microdevice previously filled with 1.2 mg/ml type I collagen, and letting them attach for 24 h, 
to create a confluent monolayer to mimic an endothelium. The endothelium integrity was first characterised 
through diffusion assays with two fluorescent dextrans (40 kDa and 70 kDa), as previously described in the litera-
ture20 (Supplementary Fig. S5). Diffusion rates were 1.91 ± 0.88 ·10−5 cm/s and 1.70 ± 0.81·10−6 cm/s, respectively 
(Supplementary Figs S5a–c & e–g), consistent with data previously reported in the literature. The diffusion pro-
files show a delayed penetration of the dextran particles through the monolayer, compared to control hydrogels 
Figure 2. Air-hydrogel interface analysis and optimization in the microdevice. (a) Schematic representation 
of the device, showing capillary forces exerted by the geometry, and capillary valves integrated into the 
design (dotted line). The scheme includes the hydrogel droplet that was placed on the top of the main inlet, to 
compensate for evaporation issues of the solution in the hydrogel and to ensure the formation of a flat hydrogel-
air interface. (b) Influence of the plasma treatment on the microdevice spontaneous filling. Left- Bright-field 
20x images showing the filling dynamics of a microdevice after plasma treatment at 0, 100, 200 and 300 ms, 
respectively; Right- Bright-field 20x images showing the filling dynamics of a microdevice without any plasma 
treatment at 0, 100, 1200 and 2500 ms, respectively. (c-f) Characterization of the hydrogel-air interface in the 
microdevice using confocal microscopy. 100x images flanked by z-stack orthogonal views of the gel interface at 
0 min after hydrogel introduction (c) and 12 min after introduction of the hydrogel, with (e) or without addition 
of a droplet of water (d). Water evaporation caused a dramatic contraction of the hydrogel (d) and FluoSpheres® 
accumulation at the interface, which formed a deep meniscus in the well. (e) Hydrogel polymerized with 
an additional hydrogel droplet placed on the main inlet during 12 min. No meniscus was observed and the 
hydrogel-air interface was flat as desired. (f) Quantification of the hydrogel height in the microwells just after 
introduction of the hydrogel (t = 0 min) and 12 min later, after gel polymerization, when no droplet was added 
on the inlet (t = 12 min. No droplet) and when a droplet was added on the inlet (t = 12 min with droplet). 
(***) p < 0.001 as calculated through Kruskal-Wallis after disproving data normality. The graph shows 
Average ± SEM – N = 10.
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(Supplementary Fig. S5d). These results indicate that the endothelial monolayer hinders the diffusion of mole-
cules, as reported in the literature20. Furthermore, results do not significantly vary between 24 and 48 hours of 
seeding.
The endothelium integrity was further characterised by immunostaining for F-Actin, VE-cadherin, and 
Nuclei. These markers allowed us not only to assess the percentage of the microwell surface area that was covered 
with cells (F-actin) but also to demonstrate the existence of cell-cell adhesions (VE-cadherin), confirming the 
endothelium is not leaky.
Figure 3. Viability of the MDA-MB231 cells grown in the microdevice in a 3D hydrogel matrix. Viable cells 
were stained with Calcein AM (green), whereas dead ones were labelled with propidium iodide (red). (a) 100x 
confocal image showing the cell viability in one microwell in the device. (b) 100x confocal image of the same 
cells grown in 2D on a Petri dish (control). (c) Quantification of the MDA-MB-231 cell viability within the 
microdevice and in Petri dishes. Welch’s t-test was performed for comparison (two-tailed distribution, α = 0.05) 
and non-significant statistical differences were found (N = 3). (d) Quantification of the cell occupied area as 
a function of the hydrogel depth. 0 µm refers to the top of the microwell (N = 10). (e) Proliferation index of 
cells cultured in the hydrogel in the microdevice, calculated by normalizing the number of cells in G2/S/M 
(as characterized by Premo FUCCI transfection in situ) with the total number of seeded cells. Data analysed 
by means of Kruskal-Wallis’ Test (N = 3). (***) p-value < 0.0001. (f) Characterization of the oxygen level 
in the device for different cell densities (0.4·106, 2·106 and 107 cells/ml) using Hypoxia-IT®. All graphs show 
average ± SEM.
www.nature.com/scientificreports/
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As presented in Fig. 4, the hydrogel surface in the microwells was entirely covered by the HUVEC cells after 
24 h, which had established cell-cell contacts across the complete area of the microwell (Fig. 4a,b, whole microwell 
images in Supplementary Image S6). Besides, no apparent gap was visible between the cells, indicating the for-
mation of a tight endothelium after 24 h of culture. The endothelium integrity was further quantified through cell 
area measurements, by comparing the surface area occupied by cells (derived from the F-actin or VE-cadherin 
fluorescence signal) with the total surface area of a microwell (Fig. 4c,f, respectively). These measurements indi-
cate that a tight endothelium was successfully created on top of each microwell.
We next evaluated the functionality of the endothelium model by treating it with pro-inflammatory factors 
such as TNF-α. TNF-α has been reported to increase endothelium permeability at concentrations of 25 and 50 
ng/ml43. As expected, after 24 h exposure to TNF-α, we observed the creation of gaps in the HUVEC monolayer 
(Fig. 4b,e). Additionally, a quantitative decrease was observed in the area occupied by cells (Fig. 4c,f), as assessed 
for both VE-cadherin and F-actin staining, and this decrease was found statistically significant for a TNF-α con-
centration of 50 ng/ml. This assay confirms that the 2D endothelium model is entirely functional and responsive 
to inflammation, as previously described in the literature20.
Co-culture model with a 2D endothelium and MDA-MB-231 breast tumour cells cultured in 3D 
in a collagen matrix. After the establishment and characterization of both the 3D tumour cell culture and 
the 2D endothelium, both elements were combined in the same microdevice.
First, the respective HUVEC and MDA-MB-231 cell distributions were investigated by imaging and after cell 
membrane staining with two different Vybrant® cell trackers: MDA-MB-231 cells were labelled in green, and 
HUVEC cells in red (Fig. 5a). As observed in separate mono-culture conditions, a flat endothelium was created 
on the top of each microwell, with a homogeneous three-dimensional distribution of the tumour cancer cells 
in the collagen matrix under the endothelium layer. Up to 24 h after cell seeding, the endothelium was found to 
be integer and tight (Supplementary Figs S7 & S8), but as time passed, changes in the endothelium appearance 
and integrity were detected. Specifically, after 48 h of co-culture after, the shape of the endothelial cells evolved 
Figure 4. Characterization of the endothelium generated on the top of the hydrogel matrix in the microdevice. 
Endothelial cells (HUVECs) were labelled with Phalloidin-TRITC (yellow) for actin staining and VE-Cadherin 
(green) for endothelial cell junction staining. (a and d) Control endothelium; (b and e) Endothelium treated 
with 50 ng/ml TNF-α for 24 h (c) Quantification of the endothelium integrity in terms of Phalloidin signal area 
for all samples (not treated, and treated with 25 and 50 ng/ml TNF-α). Samples were compared with the control. 
(*) p-value: 0.02. (f) Quantification of endothelium integrity in terms of VE-cadherin signal area for all samples 
(not treated, and treated with 25 and 50 ng/ml TNF-α). Samples were compared with the control. (**) p-value 
for 50 ng/ml TNF-α = 0.005, as calculated by Kruskal-Wallis’ Test. Graphs show average ± SEM (N = 6) and 
magnification is 200x for all images.
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Figure 5. Co-culture of MDA-MB231 tumour cells with HUVECs cells. (a) 3D reconstruction of the 2D-3D co-
culture model within the microdevice after 24 h of seeding, tumour cells being grown in the 3D hydrogel matrix 
and HUVECs as a monolayer on top of the hydrogel in the microwells. (b–g) Assessment of the integrity of the 
endothelium monolayer in the co-culture system, compared to control conditions (endothelium mono-culture). 
b- Actin staining of a control HUVEC endothelium (mono-culture). (c) Detail of a control HUVEC endothelium 
(mono-culture) stained with VE-Cadherin and NucBlue®. (d) Actin staining of a HUVEC endothelium in co-
culture with MDA-MB-231 tumour cells, 48 h after cell seeding. (e) Detail of a HUVEC endothelium in co-culture 
with MDA-MB-231 tumour cells, 48 h after seeding, stained with VE-Cadherin and NucBlue®. (f) Assessment 
of the integrity of the HUVEC endothelium for the co-culture after 24 and 48 h compared to control conditions 
(mono-culture of a HUVEC monolayer) quantified as F-actin signal area. (n = 5, p < 0.02 as calculated with 
Kruskal-Wallis’ Test) (g) Assessment of the HUVEC cell circularity for control (mono-culture) and co-culture 
conditions after 24 and 48 h. Data was normally distributed and was evaluated by means of one-way ANOVA 
(n = 20). Graphs show average ± SEM and magnification is 200x for all images.
www.nature.com/scientificreports/
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compared to control conditions (i.e., in the absence of tumour cells in the collagen), moving from a polyhedral 
shape towards a spindled one (Fig. 5e,f). The HUVEC cell circularity was further quantified in control conditions 
(mono-culture, 48 h) and after 24 h and 48 h of co-culture with the 3D tumour model (Fig. 5g), revealing a 4% 
decrease in cell circularity between the control and co-culture after 24 h (from 0.78 to 0.76). Moreover, the cell cir-
cularity decreased by 15% at 48 h of co-culture compared to the control (from 0.78 to 0.68). Next, the cell-cell con-
nections in the endothelium disappeared, as indicated by a loss in the characteristic VE-cadherin distribution for 
blood vessels. The integrity of the endothelium was quantified as before, revealing a significant decrease by 52% 
compared to control conditions. Importantly, this decrease in F-actin signal is very similar to that observed for a 
monoculture endothelium treated with 50 ng/ml of TNF-α for 24 h (Fig. 4c). Finally, to distinguish HUVEC cells 
from MDA-MB-231 cells, the co-culture experiment was performed with HUVEC cells labelled with a cell tracker 
(CMFDA) and unlabeled cancer cells. The area occupied by HUVEC diminished over the course of 48 h, which 
confirms the previous results, indicating that cancer cells disrupted the integrity of the endothelial layer (Fig. S8). 
These results altogether demonstrate that co-culture of an endothelium with MDA-MB-231 breast tumour cells 
led to the creation of a leaky vasculature, as observed in vivo in tumour-associated vessels, which should also 
present an EPR effect8,9,44.
Drug screening in the tumour-endothelium model. Since the proposed tumour-endothelium 
co-culture model exhibited this key characteristic of leaky endothelium, we decided to apply it for drug penetra-
tion assays and evaluating the EPR effect, which is particularly interesting for nanomedicines. For this drug assay, 
we chose the death ligand TRAIL (TNF-related apoptosis-inducing ligand), which was tested in its soluble form 
(60 kDa) and as a conjugate with a large unilamellar vesicle (LUV)45. Both forms were tested at a concentration of 
0.33 ng/ml for 24 h in our co-culture model to evaluate their efficiency. As for the control, PBS (drug solvent) was 
added to the culture medium with the same amount as in the drug assay, to account for the dilution of the media.
As a first step, the toxicity of both drug formulations was assessed on the endothelium alone. The drug effect 
on the endothelium was quantified as previously described in terms of changes in the endothelium integrity. No 
significant decrease in the cell occupied area was observed after treatment with both sTRAIL and LUV-TRAIL 
(Fig. 6a–d) using F-actin and VE-cadherin staining, compared to control monolayers (Fig. 6g). Nonetheless, a 
noticeable change in the fluorescence signal pattern was found, particularly in the case of F-actin expression 
(Fig. 6a,c) (whole microwell images available in Supplementary Image S9). Notably, F-Actin and VE-cadherin 
local accumulation and alignment in some regions of the microwell were observed, which is significantly different 
from the patterns obtained in control microwells. This observation is consistent with angiogenic and mitogenic 
events, as previously described in endothelial cells after TRAIL treatment46.
Before testing both drug formulations on the co-culture models, we assessed their penetration in the microw-
ells using fluorescent surrogates such as dextran nanoparticles with a comparable size to sTRAIL (70 kDa) and a 
rhodamine-conjugated LUV as a model for LUV-TRAIL. As expected, the penetration rate was much lower in the 
case of the LUV, after both 15 min and 2 h, which is to be accounted for by the larger size of the LUV-based formu-
lation. Nonetheless, both formulations could entirely penetrate across a healthy endothelium after 2 h (Fig. 6e,f), 
despite their size difference. Interestingly, the LUV vesicles seemed to aggregate and slowly sediment together 
after 2 h, since at 20 h they did not reach the bottom of the microwell. In contrast, the 70 kDa fluorescent dextran 
reached the bottom of the microwell within 2 h.
Finally, the two drugs were tested on the established co-culture model combining a HUVEC endothelium and 
a 3D tumour cell culture. Cell viability was evaluated as before in the collagen matrix using Calcein AM and PI, 
and quantified as the percentage of the microwell occupied by dead cells at each focal plane.
In absence of treatment (control conditions), moderate mortality was found. This result is consistent with the 
presence of a necrotic core, which would result from the presence of oxygen and nutrient gradients experienced 
by cells within the microdevice. Interestingly, after treatment of the co-culture with TRAIL for 24 h at 0.33 ng/
ml, viability staining revealed that both drugs induced cell death throughout the entire microwell, with however 
a decay in cytotoxicity when going deeper in the microwell (Fig. 6h).
The slope at the beginning of the curve in Fig. 6h for both sTRAIL and LUV-TRAIL is similar to that observed 
in the control. As for the area under the curve, the control presents the smallest area under the curve of all con-
ditions. Furthermore, the area under the curve for sTRAIL is 37% higher than the control (4908 ± 99.63 for the 
control and 6728 ± 83.59 for sTRAIL). As for LUV-TRAIL, the shape of the curve is very similar, but the area 
under it is 61% higher than that of sTRAIL (10831 ± 132.62).
Specifically, despite having a lower penetration rate, LUV-TRAIL induced death in a higher cell number rela-
tive to the total cell number (65% higher for the whole microwell), which confirms LUV-TRAIL it is a more active 
form of TRAIL.
Interestingly, the lower part of the 3D tumour cell culture where oxygen depletion was more pronounced 
also correlated with a lower drug efficiency. This difference could be explained by either a lower penetration rate 
of LUV-TRAIL in this area or a lower efficiency of the drug in a low-oxygen environment. Higher resistance to 
TRAIL in hypoxic microenvironments has indeed been previously described47.
Overall, we have demonstrated that the straightforward and user-friendly configuration of this microdevice 
allows reproduction of key features of tumours, which should be accounted for in drug testing assays
Discussion
Here, we reported an SU-8 multi-well microfluidic platform to study the interactions between tumour cells grown 
in 3D in a collagen matrix in microwells and a tumour-associated endothelium grown on top of the collagen 
matrix, and for drug testing assays. A key advantage of our design is that it provides easy and precise fluidic con-
trol and instantaneous self-filling of the arrays of microwells with viscous hydrogel solutions in one single pipet-
ting step, thanks to the specific geometry of the device with the presence of capillary valves and proper surface 
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Figure 6. Drug testing assay using TRAIL in both its soluble form and anchored to a LUV in the co-culture 
established models. Endothelium immunofluorescence after 24 h of exposure to 0.33 ng/ml sTRAIL (a,b) and 
0.33 ng/ml LUV-TRAIL (c,d) for Phalloidin-TRITC (yellow) and VE-Cadherin (green), respectively. (e,f) 
Diffusion/penetration assays using TRITC-labelled LUV (4 mg/ml) and TRITC-Dextran (70 kDa, 30 µM) used 
as models for the LUV-TRAIL and s-TRAIL, respectively, across an endothelium seeded on a collagen gel. (g) 
Quantification of the endothelium integrity using the Phalloidin (red) and the VE-cadherin (green) signal 
area for control conditions (no TRAIL exposure) and samples treated with both sTRAIL and LUV-TRAIL 
(p-value > 0.99 as calculated through Kruskal-Wallis’ Test). (h) Quantification of MDA-MB-231 tumour 
cell death in 3D along the device microwell depth in control conditions, and with sTRAIL and LUV-TRAIL 
treatment in the established microfluidic co-culture model. Here, 5 million MDA-MB-231 cells/ml were seeded 
in the hydrogel matrix. Graphs show average ± SEM. N = 7.
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hydrophilicity. Therefore, our device fulfils the requirements of being easy to operate by non-specialised users 
and accessible to the biomedical community, while still allowing recreating complex and physiologically relevant 
microenvironments. So far, our device comprises 3 independent arrays of microwells, but its design and mode of 
operation lend themselves well to parallelization for medium to high-throughput assays, which makes our plat-
form particularly interesting for drug testing. Furthermore, the platform is fabricated from SU-8, which presents 
a low permeability to oxygen, which is advantageous for creating hypoxic environments, as found for instance in 
tumour tissues. The use of SU-8 for now serves the purpose of developing and optimising the device, however it 
can later be developed in thermoplastic materials by injection moulding, hence contributing to wide-spreading 
the technology. Finally, the device is prepared using 90-µm thick substrates, so that it is fully compatible with in 
situ confocal microscopy examination of the cells in the 3D environment, as well as on the top of the microwells.
Here, we successively developed and thoroughly characterised 3D tumour as well as 2D endothelium models, 
before their combination within one single device. The 3D tumour model faithfully reproduced key features 
found in tumour tissues in vivo such as preferential proliferation for cells with access to more oxygen and nutri-
ents, and creation of an oxygen gradient and a hypoxic core with no cellular proliferation, providing a dense 
tissue was initially formed. Both healthy and functional endothelium, as well as a leaky endothelium, were suc-
cessfully prepared in our device, and their integrity and permeability evaluated using immunofluorescence and 
confocal microscopy. As such, our device can easily mimic vascular integrity in different physiopathological con-
ditions. Interestingly, our study particularly revealed that co-culture of a 3D tumour model with HUVEC cells 
grown in 2D resulted in the creation of a leaky endothelium, as found in tumour tissues. Next, the established 
co-culture was used for drug penetration assay across the endothelium and in the tumour tissue and testing of an 
apoptosis-inducing drug, TRAIL, evaluated here as a soluble formulation (sTRAIL) and a liposome-conjugated 
formulation (LUV-TRAIL). Our work confirmed that LUV-TRAIL is more efficient in killing cancer cells than 
its soluble counterpart, despite its lower diffusion rate48. In the future, it would be interesting to test other drugs, 
such as compounds activated in a hypoxic environment, and to include in the 3D cellular models stromal cells 
and immune cells, which are known to influence the behaviour of tumour cells and to modulate their response 
to drug treatments.
Altogether, the 3D tumor-2D endothelium co-culture model proposed in this work entails a great potential 
not only for drug screening and testing of precision medicine, given that only 5-μl samples are required for each 
assay, but also for more fundamental in vitro studies on cellular interactions in complex tumour models. As such, 
our work is entirely in line with the development and use of enhanced and clinically relevant in vitro models, 
which would allow diminishing the number of experiments conducted on animals and accelerate drug develop-
ment and approval, hence improving patients’ prognosis and life quality at a faster pace.
Methods
Microdevice fabrication and setup. The design of the device includes three independent arrays com-
posed of five different wells each, which are connected in an array by a microchannel (Fig. 1b). As the design was 
conceived to use capillarity as a driving force to spontaneously fill the whole microdevice, special care was taken 
to avoid sudden transitions in the microchannel dimensions. Additionally, capillary valves were integrated to 
constrain the liquid within the microdevice and prevent it from flowing outward the microwells.
The fabrication was carried out as follows: A thin Kapton film (125 µm thickness) was temporarily bonded on 
top of a Pyrex substrate (Fig. 1b.1). Kapton was used because of its low adhesion to SU-8, allowing easy release 
of the devices from the substrate after their fabrication. Once the Kapton film was fixed to the substrate, a first 
SU-8-50 layer was spin-coated on it, followed by a soft-bake treatment, which consists of heating the wafer up to 
65 °C for 30 min and cooling it down to room temperature. Next, another SU-8 layer was spin-coated followed by 
a second soft-bake step. Next, a 140 mJ/cm2 exposure dose was applied to cure the first layer of the device using 
a 365-nm wavelength UV lamp, followed by a post-bake step (Fig. 1b.2). Post-bake step consisted of heating the 
wafer up to 65 °C for 15 min and cooling it down to room temperature. Following this, the same procedure was 
repeated to prepare another 80-µm thick layer of SU-8 on top of the first one (spin-coating of 60 µm and 20 µm 
layers, followed by corresponding soft-bakes). A second step exposure of 140 mJ/cm2 through a mask allowed 
defining the microchannels and microwells (Fig. 1b.3). Then, a post-bake was performed followed by a develop-
ment step to remove the unexposed SU-8 material. Specifically, the wafer was immersed into an SU-8 developer 
for 5 min, followed by a rinse step in isopropanol, distilled water and a drying step using nitrogen (Fig. 1b.4). 
As a result, an open microchannel with microwell structures was fabricated. To close the microchannel and 
define the microwells, another wafer was processed as before: a 90-µm thick SU-8 layer was processed (spun and 
soft-baked) on top of another Kapton film temporary bonded to a Pyrex wafer (Figs 1b.2 and 1b.6). Inlets, outlets, 
and microwells were defined by photolithography using the same exposure and baking parameters as before. The 
second wafer was finally developed (Fig. 1b.7). Next, both wafers (bottom and cover) were aligned and bonded 
to each other by applying a pressure of 1 bar and heating up to 90 °C for 15 min (Fig. 1b.8). Finally, the bonded 
SU-8 devices were manually released from the Kapton (Fig. 1b.9). The final thickness of the device was sufficient 
to ensure mechanical rigidity and easy handling in the absence of a supporting substrate.
For easy introduction of the hydrogel and hydrogel confinement, the SU-8 was rendered hydrophilic through 
an oxygen plasma treatment analogous to that described in Jokinen et al.49, consisting of an 80 s treatment at 
300 W, using a pressure of 0.4 mbar and 50% O2 to flood the chamber.
Air-hydrogel interface analysis and optimization in the microdevice. 100 μl of hydrogel mixture 
was prepared as follows to yield a final collagen concentration of 1.2 mg/ml:
36.60 µl of a 3.37 mg/ml stock solution of Type I rat tail Collagen (Corning, 354236) was neutralized by adding 
0.9 µl NaOH at 1 M (Sigma 221465). Ionic strength was adjusted by adding 20 µl of DMEM 5x (Sigma, D5030). 
Finally, the volume was adjusted to 100 μl by adding sterile distilled water. Using a chilled tip, 5 μl droplets of the 
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resulting collagen preparation were placed on top of each inlet to allow spontaneous filling of the microdevice. 
Afterwards, the microfluidic device was placed in an incubator (37 °C and 5% CO2) upside down for 12 min for 
collagen polymerization.
To assess the effect of evaporation at the hydrogel interface, a 1.2 mg/ml collagen gel was supplemented with 
0.2 µm FluoSpheres® (Thermo-Fisher, ref. F-8811) diluted to a final concentration of 1:100 from the stock solu-
tion. The resulting collagen mixture was sonicated for 5 min at 4 °C before use to ensure proper dispersion of the 
Fluospheres®.
Microdevice biocompatibility and characterization of the 3D cell culture microenviron-
ment. Cell isolation and culture. MDA-MB-231 cells, derived from breast adenocarcinoma, were kindly 
provided by Dr Joan Massagué (Memorial Sloan-Kettering Cancer Centre). MDA-MB-231 cells were rou-
tinely grown in high glucose-DMEM culture medium (Lonza BE12-614F) supplemented with 10% FBS (Sigma 
F7524) and 2 mM L-glutamine (Lonza17-605C) and 1% penicillin (1000 U/ml), 1% streptomycin (1000 µg/ml) 
(Penicillin/Streptomycin, Lonza DE 17-602E) within a humidified TEB-1000 incubator set at 5% CO2, 20% O2 
and 37 °C (EBERS Medical Technology). Media was refreshed every other day and cells were passaged every 4 
days using a Trypsin/EDTA solution (Lonza, CC-5012).
Human Umbilical Vein Endothelial Cells (HUVECs) were extracted at the Miguel Servet Hospital (Zaragoza, 
Spain) from healthy donors after informed consent according to current ethical regulations. Isolation was per-
formed according to Crampton et al.50 from umbilical cords 1-3 h after delivery. A fraction of the isolated cells 
was tested using a FACSAria (BD) flow cytometer to confirm cell positiveness for the endothelial markers CD31, 
CD105, CD146 and negative for CD45. After testing, HUVEC cells were cultured in EGM-2 culture medium 
(Lonza CC-3176) prepared according to the manufacturer’s instructions. Only passages 2-4 cells were used for 
experiments.
The angiogenic potential of HUVEC cells was confirmed as previously reported by DeCicco-Skinner51 by 
seeding the extracted HUVECs on top of a Matrigel® (Corning, 354248) -filled microdevice at a final density of 
20,000 cells/cm2 (Supplementary Fig. S1).
Cell culture in microdevices. For 3D cell culture, a 100 μl of hydrogel mixture with a final collagen con-
centration of 1.2 mg/ml was prepared as before; however, in the last step, the volume was first adjusted to 50 μl by 
adding sterile distilled water before adding 50 µl of an MDA-MB-231 cell suspension. The resulting cell suspen-
sion in hydrogel was carefully homogenized by pipetting up and down several times. Next, the device was filled 
with the mixture and the hydrogel was polymerized as described above.
To prepare a HUVEC monolayer on top of the collagen in the microwells, HUVEC cells were trypsinized, 
counted and resuspended in EGM-2. Cells were seeded on top of the microdevice at a final density of 250,000 
cells/cm2 (saturating concentration). Media was refreshed every other day in the microdevice.
Cell viability staining. Microdevices were incubated for 15 min in Calcein AM (Invitrogen ref. C3100MP) 
and propidium iodide (PI) (Sigma-Aldrich, P4170) in Phosphate Buffered Saline (PBS) (Lonza 17-516 F) at final 
concentrations of 1 μg/ml and 4 μg/ml, respectively, to assess cell viability. Confocal Z-stacks were acquired for 
each microwell and throughout the entire height of the microwell at 100x magnification.
Immunofluorescence staining. HUVEC cells in the microdevices were washed with PBS and fixed with 
3.7% paraformaldehyde overnight at 4 °C. The following steps were performed at room temperature unless speci-
fied otherwise. Cells were permeabilized using 0.1% Triton X-100 (Sigma, T8787) for 5 min and blocked with 1% 
BSA (Sigma, A1933) for 30 min. Samples were washed twice with 0.05% Tween-20 (Sigma P2287) in PBS between 
every step.
To quantify endothelium integrity (i.e. the percentage of the microwell surface area covered by HUVEC cells 
seeded on top of the microdevices), HUVEC cells were stained for VE-cadherin, Actin, and Nuclei. Microdevices 
were incubated with VE-Cadherin D87F2 XP Rabbit mAb (Cell Signaling 2500 S) in 1% BSA, 0.1% Triton X-100 
PBS overnight at 4 °C and washed thrice with 0.05% Tween-20 PBS (Sigma-Aldrich ref. P2287). Next, microde-
vices were incubated with Alexa Fluor 488 Donkey anti-rabbit IgGs (ThermoFischer A-21206), Phalloidin-TRITC 
for actin staining and Nucblue® Fixed Cell Stain ReadyProbes® for nuclei staining (Life Technologies R37606) for 
an hour. Finally, microdevices were washed thrice with 0.05% Tween-20 PBS.
Endothelial integrity in the presence of tumour cells was fluorescently tracked overtime using fluorescence 
microscopy after staining the HUVEC cells with CMFDA Cell Tracker (Thermo-Fisher C2925). CMFDA was first 
dissolved at 1 mM in DMSO and used according to the manufacturer’s instructions.
Oxygen-sensing staining. The variations in the oxygen concentration in the 3D culture within the 
microdevice was assessed using the oxygen-sensitive dye Image-iT® Hypoxia Reagent (Life Technologies, 
H10498) and confocal microscopy. This reagent exhibits increased fluorescence upon decrease of the oxygen ten-
sion inside the cell. Image-iT® was initially dissolved in DMSO at a concentration of 1 mM and used according 
to the manufacturer’s instructions.
The fluorescent response of Image-iT® to different oxygen tensions was first calibrated via sodium sulphite 
addition, which is a known oxygen absorption agent52. Cells were plated at 1000 cells/cm2 and Image-iT® was 
added 24 h later. A 2% solution of sodium sulphite (Sigma Aldrich, 08981) was added to yield final concen-
trations in sodium suphite of 0.25, 0.5, 0.75 and 1%. The fluorescent response of the oxygen-sensitive dye was 
imaged using confocal microscopy (Supplementary Fig. S3a–c). Its response was further validated with cells 
pre-conditioned at 1% oxygen overnight in a hypoxia incubator (TEB-100®, EBERS Medical Technologies) 
(Supplementary Fig. S3d,f).
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Cells were embedded in 1.2 mg/ml collagen hydrogel at three different densities (0.4 × 106, 2 × 106 and 107 
cells/ml) taking advantage of the independent microwell arrays included in the design. 24 hours after seeding, 
the oxygen-sensitive dye was added, and cell-induced oxygen gradients within the microwells were imaged for 
concentrations of 0.4 × 106 and 107 cells/ml.
Proliferation staining. Cell proliferation was characterised in live cells using the Premo Fucci® Cell Cycle 
Sensor (Thermo P36237), similarly as in our previous work53. Briefly, cells were seeded in 3D as previously 
described, at three different cell densities (0.4 × 106, 2 × 106 and 107 cell/ml) in the three independent microw-
ell arrays included in the design. Cells were transfected in situ 4 h after seeding, using ca. 50 virus particles per 
cell during 24 h. This cell cycle sensor was transduced into the cells by using two different reporters coupled to 
TagRFP (red) or emGFP (green), which are expressed alternatively during the G1 phase or the S/G2/M phases, 
respectively.
Live cell membrane staining. With the aim of distinguishing HUVEC cells from MDA-MB-231 cells 
when combined in the same microdevice, Vybrant® DiI and DiO were, respectively, used according to the man-
ufacturer’s instructions. Briefly, cells were trypsinized from the culture dish and resuspended in relevant media 
to inactivate Trypsin. Cells were then pelleted and resuspended in serum-free medium to a concentration of 1 
million cells/ml. A solution containing 5 µl of Vybrant® stock per ml of media was added to each cell suspension 
and cells were incubated with the dye for 15 min at 37 °C in the dark. Finally, cells were thoroughly washed with 
PBS and resuspended in EGM-2 medium for further use.
Preparation of soluble recombinant TRAIL and anchoring to lipid vesicles. Once the co-culture 
model was established, it was applied to test the two TRAIL-based formulations: human soluble recombinant 
TRAIL (sTRAIL) and Large Unilamellar Vesicles (LUV) with sTRAIL anchored to their surface (LUV-TRAIL). 
LUV-type liposomes coated with sTRAIL were prepared as previously described36,54,55. The lipid composition 
consisted of a mixture of phosphatidylcholine, sphingomyelin, cholesterol, and 1,2-dioleoyl-sn-glycero-3-[[N-
(5-amino-1-carboxypentyl)-iminodiacetic acid]succinyl](nickel salt) (Avanti Polar Lipids) in a 55:30:10:5 weight 
ratio to mimic the human exosome lipid composition. sTRAIL corresponding to amino acids 95–281 cloned into 
the pET-28c plasmid (Novagen - kindly provided by Dr. M. MacFarlane)19 with a 6-histidine tag was attached 
to the liposome surface as previously described56. Generated LUV-TRAIL was characterised as described else-
where54 and stored at 4 °C until use.
Drug diffusion assays. To assess the penetration rate across the endothelium and through the hydrogel for 
the different compounds, the microdevices were prepared as described in previous sections and filled with colla-
gen as described in sections 2.1 and 2.2. Microdevices were covered with a 4 mg/ml TRITC-LUVs, 30 μM TRITC 
70 kDa Dextran solution or 30 μM FITC 40 kDa Dextran solution, and Z-stack confocal images were taken for at 
least 2 h throughout the entire microwell height. The diffusion rate was calculated as the change in position of the 
50% intensity value over the observed time.
Imaging. Phase contrast and fluorescence microscopy images were taken using a Nikon Eclipse Ti® inverted 
fluorescence microscope equipped with a C1 modular confocal microscope system. To acquire whole microwell 
images, 250-μm thick confocal stacks were performed, by taking images every 10 μm. Finally, a thermostated 
chamber within the microscope was equilibrated to 37 °C and 5% CO2 whenever live cell imaging was performed.
Image analysis and processing. Image analysis was performed using Fiji® (http://fiji.sc/Fiji). In order to 
analyse cell viability, viable and dead cells were counted manually, whereas cell distribution and marker expres-
sion were quantified as the percentage of the microwell area where the marker was being expressed. Finally, cell 
circularity was assessed manually for at least 20 cells in each sample.
Statistical analysis. Results are presented as the mean ± standard error. The normal distribution was tested 
by the Kolmogorov-Smirnov test. Statistical significance was set at p < 0.05. For nonparametric comparisons, a 
Kruskal-Wallis test was performed followed by the Mann-Whitney U-test.
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